Design Therapeutics, Inc. DSGN
Design Therapeutics, Inc. (Nasdaq: DSGN) is a rare genetic drug developer. Its lead program, DT-216P2, is in Phase 2 for Friedreich ataxia (FA). Its next catalyst on record is DT-216P2 (FA): Update on registrational plans (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: DT-216P2 (FA) — Update on registrational plans (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DT-216P2 | Friedreich ataxia (FA) | small molecule | Phase 2 |
| DT-168 | Fuchs endothelial corneal dystrophy (FECD) | small molecule | Phase 2 |
| DT-818 | Myotonic dystrophy type-1 (DM1) | small molecule | Phase 1 |
| HD GeneTAC candidate molecules | Huntington's disease (HD) | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.